Abbisko Collaborates with Lilly
Abbisko enters strategic research collaboration and license agreement with Lilly, eligible for up to $1.9B in milestones
Will conduct discovery and early development activities for novel drug programs directed against disease targets selected by Lilly. 9B, plus tiered royalties based on annual net sales of products arising from the collaboration. - Abbisko and Lilly previously entered a global collaboration and exclusive license agreement in 2022 to collaborate on the discovery, development and potential commercialization of a novel small-molecule therapeutic.